These observations are consistent with those of a recent study that demonstrated that the TGFβ1-Smad signaling axis is responsible for the maintenance of specific epigenetic modifications that favor the EMT and prometastatic phenotypes in breast cancer. The gene discussed is TGFB1; the disease is breast cancer.